GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » PE Ratio

Theralink Technologies (Theralink Technologies) PE Ratio : At Loss (As of May. 23, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-23), Theralink Technologies's share price is $0.0007. Theralink Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00. Therefore, Theralink Technologies's PE Ratio for today is At Loss.

During the past 13 years, Theralink Technologies's highest PE Ratio was 155.34. The lowest was 0.00. And the median was 120.82.

Theralink Technologies's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00.

As of today (2024-05-23), Theralink Technologies's share price is $0.0007. Theralink Technologies's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00. Therefore, Theralink Technologies's PE Ratio without NRI ratio for today is At Loss.

During the past 13 years, Theralink Technologies's highest PE Ratio without NRI was 183.01. The lowest was 0.00. And the median was 142.34.

Theralink Technologies's EPS without NRI for the three months ended in Dec. 2023 was $-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 47.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 79.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 73.40% per year.

During the past 13 years, Theralink Technologies's highest 3-Year average EPS without NRI Growth Rate was 93.50% per year. The lowest was -2190.90% per year. And the median was 38.80% per year.

Theralink Technologies's EPS (Basic) for the three months ended in Dec. 2023 was $-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00.

Back to Basics: PE Ratio


Theralink Technologies PE Ratio Historical Data

The historical data trend for Theralink Technologies's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralink Technologies PE Ratio Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Theralink Technologies's PE Ratio

For the Biotechnology subindustry, Theralink Technologies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralink Technologies's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's PE Ratio distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's PE Ratio falls into.



Theralink Technologies PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Theralink Technologies's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.0007/-0.004
=-0.18(At Loss)

Theralink Technologies's Share Price of today is $0.0007.
Theralink Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Theralink Technologies  (OTCPK:THER) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Theralink Technologies PE Ratio Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralink Technologies (Theralink Technologies) Business Description

Traded in Other Exchanges
N/A
Address
15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.
Executives
Danica Holley director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz director 15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors director 1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin director, officer: Chief Executive Officer HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc 10 percent owner 1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett officer: Chief Executive Officer 230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb director PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman 10 percent owner, officer: Chief Operating Officer-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme director, 10 percent owner, officer: Global Operations GM-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman director C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: CFO & President 549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head director, officer: Chief Executive Officer 6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817

Theralink Technologies (Theralink Technologies) Headlines